3,4-Dichloroisocoumarin

Identification

Name
3,4-Dichloroisocoumarin
Accession Number
DB04459  (EXPT01202)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Average: 215.033
Monoisotopic: 213.958834786
Chemical Formula
C9H4Cl2O2
InChI Key
SUGXUUGGLDCZKB-UHFFFAOYSA-N
InChI
InChI=1S/C9H4Cl2O2/c10-7-5-3-1-2-4-6(5)9(12)13-8(7)11/h1-4H
IUPAC Name
3,4-dichloro-1H-isochromen-1-one
SMILES
ClC1=C(Cl)C2=CC=CC=C2C(=O)O1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UComplement factor DNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Illicit, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental, Investigational
AmineptineThe serum concentration of Amineptine can be increased when it is combined with 3,4-Dichloroisocoumarin.Illicit, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
AmitriptylinoxideThe serum concentration of Amitriptylinoxide can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
AmoxapineThe serum concentration of Amoxapine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
BoceprevirThe serum concentration of 3,4-Dichloroisocoumarin can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
ButriptylineThe serum concentration of Butriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
CarbamazepineThe metabolism of 3,4-Dichloroisocoumarin can be increased when combined with Carbamazepine.Approved, Investigational
ClarithromycinThe therapeutic efficacy of Clarithromycin can be decreased when used in combination with 3,4-Dichloroisocoumarin.Approved
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational, Vet Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational, Vet Approved
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
DibenzepinThe serum concentration of Dibenzepin can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with 3,4-Dichloroisocoumarin.Approved, Investigational
DimetacrineThe serum concentration of Dimetacrine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Withdrawn
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
DoxepinThe serum concentration of Doxepin can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational, Vet Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved
GarlicThe serum concentration of 3,4-Dichloroisocoumarin can be decreased when it is combined with Garlic.Approved, Nutraceutical
ImipramineThe serum concentration of Imipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
IprindoleThe serum concentration of Iprindole can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
LofepramineThe serum concentration of Lofepramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
MelitracenThe serum concentration of Melitracen can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental, Investigational
MestranolThe serum concentration of Mestranol can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Illicit
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Withdrawn
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
OpipramolThe serum concentration of Opipramol can be increased when it is combined with 3,4-Dichloroisocoumarin.Investigational
PethidineThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Pethidine.Approved
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
RiociguatThe serum concentration of Riociguat can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
St. John's WortThe metabolism of 3,4-Dichloroisocoumarin can be increased when combined with St. John's Wort.Approved, Investigational, Nutraceutical
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with 3,4-Dichloroisocoumarin.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when 3,4-Dichloroisocoumarin is combined with Temsirolimus.Approved
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
TipranavirThe serum concentration of 3,4-Dichloroisocoumarin can be decreased when it is combined with Tipranavir.Approved, Investigational
TriazolamThe serum concentration of Triazolam can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with 3,4-Dichloroisocoumarin.Approved
Valproic AcidThe serum concentration of Valproic Acid can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved, Investigational
VerapamilThe metabolism of Verapamil can be decreased when combined with 3,4-Dichloroisocoumarin.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with 3,4-Dichloroisocoumarin.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
1609
PubChem Substance
46507031
ChemSpider
1550
BindingDB
50199883
ChEBI
109540
ChEMBL
CHEMBL24983
HET
DIC
PDB Entries
1dic

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0697 mg/mLALOGPS
logP3.14ALOGPS
logP2.88ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)-7.1ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area26.3 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity61.05 m3·mol-1ChemAxon
Polarizability18.65 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9883
Blood Brain Barrier+0.9664
Caco-2 permeable+0.834
P-glycoprotein substrateNon-substrate0.6847
P-glycoprotein inhibitor INon-inhibitor0.8822
P-glycoprotein inhibitor IINon-inhibitor0.9616
Renal organic cation transporterNon-inhibitor0.8565
CYP450 2C9 substrateNon-substrate0.7781
CYP450 2D6 substrateNon-substrate0.8749
CYP450 3A4 substrateNon-substrate0.6444
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorInhibitor0.8948
CYP450 2D6 inhibitorNon-inhibitor0.9345
CYP450 2C19 inhibitorNon-inhibitor0.6684
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7832
Ames testNon AMES toxic0.7865
CarcinogenicityNon-carcinogens0.9227
BiodegradationNot ready biodegradable0.9632
Rat acute toxicity3.4558 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8705
hERG inhibition (predictor II)Non-inhibitor0.9511
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as isocoumarins and derivatives. These are polycyclic compounds containing an isochromane which bears a ketone at the carbon C1.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Isocoumarins and derivatives
Sub Class
Not Available
Direct Parent
Isocoumarins and derivatives
Alternative Parents
2-benzopyrans / Pyranones and derivatives / Benzenoids / Aryl chlorides / Heteroaromatic compounds / Lactones / Oxacyclic compounds / Organooxygen compounds / Organochlorides / Organic oxides
show 1 more
Substituents
Isocoumarin / Benzopyran / 2-benzopyran / Pyranone / Benzenoid / Pyran / Aryl halide / Aryl chloride / Heteroaromatic compound / Lactone
show 9 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Serine-type peptidase activity
Specific Function
Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate pathway. Its function is homologous to th...
Gene Name
CFD
Uniprot ID
P00746
Uniprot Name
Complement factor D
Molecular Weight
27032.66 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on June 02, 2018 07:30